Physician profile
Roger D Annis
NPI 1952350480
$2,880.12
in general payments reported to CMS, 2019-2025
32 companies · $14.83 in 2025
The $14.83 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $593 · 2020: $914 · 2021: $1,340 · 2024: $19.00 · 2025: $14.83.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $33.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $33.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $411.19 | 2019-2021 | |
| Glaxosmithkline, LLC. | $294.54 | 2019-2021 | |
| Novo Nordisk INC | $291.05 | 2019-2024 | Rybelsus, Ozempic |
| Lilly USA, LLC | $218.38 | 2020-2025 | Zepbound, Mounjaro |
| Sanofi-Aventis U.S. LLC | $166.47 | 2019-2021 | |
| Amarin Pharma, INC. | $162.67 | 2019-2021 | |
| Abbvie INC. | $157.61 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $156.80 | 2020-2021 | |
| Astellas Pharma US INC | $135.64 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $117.36 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $101.82 | 2021 | |
| Pfizer INC. | $94.02 | 2019-2021 | |
| Hologic Sales and Service, LLC | $69.93 | 2020 | |
| Merck Sharp & Dohme LLC | $63.67 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $62.49 | 2019-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $43.74 | 2020 | |
| Janssen Pharmaceuticals, INC | $43.21 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.09 | 2021 | |
| Eisai INC. | $30.80 | 2021 | |
| Adlon Therapeutics L.P. | $29.13 | 2020-2021 | |
| Shire North American Group INC | $26.56 | 2019 | |
| Genentech USA, INC. | $19.89 | 2019 | |
| Sobi, INC | $18.74 | 2019 | |
| Clarus Therapeutics INC. | $17.88 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.25 | 2019 | |
| Harmony Biosciences LLC | $15.05 | 2020 | |
| Radius Health, INC. | $14.89 | 2019 | |
| Esperion Therapeutics, INC. | $14.70 | 2021 | |
| Daiichi Sankyo INC. | $13.97 | 2019 | |
| Ironshore Pharmaceuticals INC. | $13.85 | 2019 | |
| Jazz Pharmaceuticals INC. | $12.76 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $11.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Annis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.